HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
2.790
-0.150 (-5.10%)
At close: Jul 2, 2026, 4:00 PM EDT
2.834
+0.044 (1.58%)
After-hours: Jul 2, 2026, 7:23 PM EDT
HeartSciences Revenue
HeartSciences had revenue of $8.67K in the twelve months ending January 31, 2026. In the fiscal year ending April 30, 2025, HeartSciences had annual revenue of $4.35K, down -76.61%.
Revenue (ttm)
$8.67K
Revenue Growth
-76.61%
P/S Ratio
1,025.40
Revenue / Employee
$578
Employees
15
Market Cap
8.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.35K | -14.25K | -76.61% |
| Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
| Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
| Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
| Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
| Apr 30, 2020 | 64.18K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 19.57M |
| Beyond Air | 7.68M |
| Biomerica | 4.33M |
| VolitionRx | 2.47M |
| Sintx Technologies | 1.03M |
| Co-Diagnostics | 718.17K |
| Nexalin Technology | 275.58K |
HSCS News
- 8 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 8 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 8 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 9 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 10 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 11 days ago - HeartSciences, Fortitude announces business combination - TheFly
- 11 days ago - HeartSciences Proxy statement: Proxy filing - Filings
- 11 days ago - HeartSciences Proxy statement: Proxy filing - Filings